OncoMatch/Clinical Trials/NCT07081022
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Is NCT07081022 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including JS203 in combination with gemcitabine and oxaliplatin and JS203 in combination with ifosfamide, carboplatin and etoposide for b-cell non-hodgkin's lymphoma.
Treatment: JS203 in combination with gemcitabine and oxaliplatin · JS203 in combination with ifosfamide, carboplatin and etoposide · JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone · JS203 combined with lenalidomide — To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression
B-cell non-Hodgkin's lymphoma expressing CD20 antigen
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CD20-CD3 bispecific antibody
Previously received CD20-CD3 bispecific antibody treatment
Cannot have received: allogeneic hematopoietic stem cell transplantation
Previous allogeneic hematopoietic stem cell transplantation
Cannot have received: solid organ transplantation
Previous solid organ transplantation
Lab requirements
Blood counts
Kidney function
Liver function
Acceptable organ function at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify